ATE123147T1 - Materialzusammensetzung, welche ein polypeptid aus pankreas-insel-amyloid und/oder antikörpern gegen dieses polypeptid enthält, und anwendung dieser zusammensetzung. - Google Patents

Materialzusammensetzung, welche ein polypeptid aus pankreas-insel-amyloid und/oder antikörpern gegen dieses polypeptid enthält, und anwendung dieser zusammensetzung.

Info

Publication number
ATE123147T1
ATE123147T1 AT87850300T AT87850300T ATE123147T1 AT E123147 T1 ATE123147 T1 AT E123147T1 AT 87850300 T AT87850300 T AT 87850300T AT 87850300 T AT87850300 T AT 87850300T AT E123147 T1 ATE123147 T1 AT E123147T1
Authority
AT
Austria
Prior art keywords
polypeptide
antibodies
composition containing
pancreas island
composition
Prior art date
Application number
AT87850300T
Other languages
English (en)
Inventor
Per Westermark
Kenneth H Johnson
Original Assignee
Westermark P
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20365860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Westermark P, Univ Minnesota filed Critical Westermark P
Application granted granted Critical
Publication of ATE123147T1 publication Critical patent/ATE123147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/845—Pancreas
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87850300T 1986-10-08 1987-10-07 Materialzusammensetzung, welche ein polypeptid aus pankreas-insel-amyloid und/oder antikörpern gegen dieses polypeptid enthält, und anwendung dieser zusammensetzung. ATE123147T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8604270A SE454299B (sv) 1986-10-08 1986-10-08 Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden

Publications (1)

Publication Number Publication Date
ATE123147T1 true ATE123147T1 (de) 1995-06-15

Family

ID=20365860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87850300T ATE123147T1 (de) 1986-10-08 1987-10-07 Materialzusammensetzung, welche ein polypeptid aus pankreas-insel-amyloid und/oder antikörpern gegen dieses polypeptid enthält, und anwendung dieser zusammensetzung.

Country Status (10)

Country Link
US (2) US5116948A (de)
EP (1) EP0263802B1 (de)
JP (2) JP2863527B2 (de)
AT (1) ATE123147T1 (de)
AU (1) AU8101287A (de)
CA (1) CA1341222C (de)
DE (1) DE3751316T2 (de)
ES (1) ES2072252T3 (de)
SE (1) SE454299B (de)
WO (1) WO1988002863A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298605A (en) * 1986-10-08 1994-03-29 Regents Of The University Of Minnesota Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5352771A (en) * 1992-08-31 1994-10-04 Iowa State University Research Foundation Inc. Hydrolysis of peptide bonds using Pt (II) and Pd (II) complexes
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1996002269A1 (en) * 1994-07-13 1996-02-01 Auckland Uniservices Limited Therapeutic method and compounds of use therein
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2006010533A2 (en) * 2004-07-28 2006-02-02 F. Hoffmann-La Roche Ag Pancreatic polypeptide as target/marker of beta cell failure
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
JP7505713B2 (ja) * 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE500044C2 (sv) * 1985-02-15 1994-03-28 Gambro Lundia Ab Peptidförening, antiserum framställt med användning av denna förening samt användning av föreningen
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides

Also Published As

Publication number Publication date
US5112945A (en) 1992-05-12
JPH02500857A (ja) 1990-03-22
SE8604270D0 (sv) 1986-10-08
EP0263802A1 (de) 1988-04-13
JP2863527B2 (ja) 1999-03-03
AU8101287A (en) 1988-05-06
CA1341222C (en) 2001-05-01
JP2939439B2 (ja) 1999-08-25
JPH09119929A (ja) 1997-05-06
DE3751316D1 (de) 1995-06-29
WO1988002863A1 (en) 1988-04-21
SE454299B (sv) 1988-04-18
ES2072252T3 (es) 1995-07-16
DE3751316T2 (de) 1996-02-01
EP0263802B1 (de) 1995-05-24
US5116948A (en) 1992-05-26

Similar Documents

Publication Publication Date Title
ATE123147T1 (de) Materialzusammensetzung, welche ein polypeptid aus pankreas-insel-amyloid und/oder antikörpern gegen dieses polypeptid enthält, und anwendung dieser zusammensetzung.
ES2056817T3 (es) Transformacion de trichoderma.
DE69228701D1 (de) Fragmente von Prion Proteinen.
JPS5690048A (en) Novel polypeptides* their manufacture* medicinal composition containing them and their use
DE3382760D1 (de) Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
NO833793L (no) Cystein-manglende muteiner av biologisk aktive proteiner
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
NO864139L (no) Polypeptid virksomt ved dannelse av aids-antistoff.
EP0151246A3 (en) Polypeptide inhibitor of the activity of alpha-amylase, process for its preparation, its use, and pharmaceutical preparations
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DK228190D0 (da) Rajgraespollenallergen
ES8802457A1 (es) Un procedimiento para la preparacion de polipeptidos inmunogenicos
SE8503228L (sv) Ny beta-urogastron-gen
ES2101716T3 (es) Vectores y compuestos para la expresion de mutantes de glicosilacion de la proteina c humana.
ATE196775T1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE3889851D1 (de) Verfahren und Materialien zur Herstellung der Lösungen von metallmarkierten Antikörpern.
DE3889255D1 (de) Aktiver Wirkstoff und diesen enthaltendes Arzneimittel zur Verhinderung oder Bekämpfung der Abstossung von Organtransplantaten.
DE59007794D1 (de) Verfahren zur Herstellung von 2-Chlor-5-chlormethyl-pyridin und neue Zwischenprodukte.
ES2074591T3 (es) Expresion de polipeptidos de vih 1 y 2 y su utilizacion.
ATE97959T1 (de) Monoklonale antikoerper gegen menschliche alphaatrialnatri¨retic-polypeptide und entsprechende hybridome, deren herstellung und verwendung.
DK329789D0 (da) Monoklonalt antistof
FI892912A7 (fi) Koostumus tekokivimateriaalien valmistamiseksi
FR1203811A (fr) Agrafe de fixation de feuillets réalisée en matière artificielle ou matière analogue et procédé pour la réalisation de cette agrafe
ATE110775T1 (de) Verfahren zur herstellung von hirudin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time